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ABSTRACT  
Silymarin is polyphenolic flavonoid obtained from the seeds of silybum marianum plant. It has various pharmacological properties such as 
hepatoprotective, anti-inflammatory, antioxidant, anti-carcinogenic, hypolipidemic properties. Silymarin has recently reported to be 
neuroprotective agent against neurodegenerative disease such as Alzheimer, Parkinson’s and cerebral ischemia. It contains eight active 
components, among which silibinin is the most active component. However, silymarin is BCS class II drug which having poor bio availability due 
to extensive phase II metabolism, poor aqueous solubility, low permeability across intestinal epithelial cells and rapid excretion in bile and 
urine.  Therefore, it is necessary to understand all formulations and analytical aspects including all possible future prospects. In this review a 
potential approach to enhance solubility, bioavailability and to develop a robust formulation is studied. The number of studies describes novel 
drug delivery system (NDDS) based formulations have been significantly increased. The raise in novel drug delivery exploitation is essentially 
due to defeated barriers within technological process of lipid based nanoparticles formulations and increased knowledge of underlying 
mechanisms of transport of NDDS via different route of administration. This review focuses on pharmacological properties of s ilymarin, 
challenges, benefits and application of novel drug delivery system. To reduce the adverse effects and toxicities novel drug delivery will be an 
attractive approach of current therapies. 
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INTRODUCTION: 
Silymarin is obtained from the extracts of seeds and fruits of 
Silybum marianum plant it’s common name is milk thistle 
and it is chemically known as 2-(2,3-dihydro-2-(4-hydroxy-
3-methoxyphenyl)-3-(hydroxymethyl)-1,4-benzodioxin-6-
yl)-2,3-dihydro-3,5,7-trihydroxy4H-1-benzopyran-4-one1. It 
is one of the oldest and thoroughly researched plants of 
ancient times used as herbal medicine and food supplement 
for the treatment of various diseases associated with liver 
and gallbladder, hepatitis, cirrhosis, jaundice and protection 
against amanita phalloides mushroom and other toxin 
poisonings. The silymarin is composed of three isomer 
flavonolignans: silybin, silydianin, isosilibinin and 
silychristin2. Silybin (silibinin) is the most active component 
of silymarin3. Silybin is the mixture of two diastereomers A 
and B in approximately 1:1 propoportion containing 
therapeutic properties such as antioxidant, anti-
inflammatory, anti-carcenogenic, neuroprotective, 
hepatoprotective, cardioprotective properties.  
In polar aprotic solvents (eg. acetone, N, N-
dimethylformanide, and tetrahydrofuran) silybin is highly 
soluble, in polar protic solvents (e.g ethanol and methanol) it 
is poorly soluble and in non-polar solvents (eg. chloroform 
and petroleum ether) it is insoluble. The pharmacokinetics 
studies showed that the oral administration of silymarin is 
only 23-47% absorbed from gastrointestinal tract where it 
undergoes enterohepatic circulation4,5. It is metabolized by 
CYP450-2C8 to mono and dihydroxy silybin (minor) and o-
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demethylated silybin (major) metabolites6. During the phase 
II metabolism multiple conjugation reactions are observed it 
includes formation of silybin monoglucoronide, silybin 
diglucoronide, silybin monosulfate, and silybin diglucoronide 
sulfate7. The small amount of absorbed silybin is excreted in 
kidney and about 18% is excreted in the bile after 
conjugation with sulfate and glucuronide. The reported 
clearance half-life of silymarin is 6–8 hours8. Poor aqueous 
solubility, high metabolism, poor penetration across 
epithelial cells, rapid systemic excretion these are main 
reasons for limited bioavailability of silybin. To overcome 
these issues, novel drug delivery has shown great potential 
using different formulations like liposomes, microspheres, 
solid dispersion, emulsions, dendrimers, solid lipid 
nanoparticles, nanosuspension, nanocrystals, inclusion 
complex, micelles,  to improve the aqueous solubility, 
penetration ability and to enhance bioavailability.
 
 
Figure 1: Classification of flavonoids 
 
PHARMACOLOGICAL PROPERTIES:  
Silymarin shows antioxidant properties and acts as a free 
radical scavenger that induces lipid peroxidation and also 
influences enzyme systems associated with glutathione and 
superoxide dismutase9. In pre-clinical study silymarin and 
silybin are agents found to be liver protective in mouse and 
rats against hepatotoxicity induced by different agents such 
as carbon tetrachloride, ethanol intoxication, cisplatin, 
acetaminophen, thioacetamide10. The silymarin shows action 
on lung cancer, breast cancer, ovarian cancer, cervical 
cancer, skin cancer, prostate cancer, liver carcinoma, bladder 
cancer. Silybin induced MCF7 breast cancer cells to undergo 
autophagic cell death and observed formation of autophagy 
related genes i.e Atg12-Atg5, Beclin-1 upregulation and Bcl-2 
downregulation11. In breast cancer T47 cell line decreases in 
miR-21, miR-15a and miR-141 while increases in miR-200c 
expression levels when treated with silibinin12. Silybin 
shows anticancer effect on both androgen-dependent and 
androgen-independent prostate cancer by inhibiting cell 
growth, cell invasion and metastasis. The epithelial to-
mesenchymal transitions are targeted by silybin in which 
epithelial characteristics are stimulated and the expressions 
of mesenchymal markers are inhibited. Silybin treatment for 
prostate cancer resulted in cytokeratin-18 up regulation and 
viment down regulation13. Silybin shows time and dose 
dependent apoptotic action on human bladder transitional 
cell carcinoma (TCC) which is related to cleavage of caspase 
3 and poly(ADP-ribose) polymerase14. 
The most active component of silymarin i.e silybin contains 
anti-inflammatory properties by inhibiting the 
prostaglandins and leukotrienes from polyunsaturated fatty 
acids in the liver and enzyme lipoxygenase. The potential of 
silybin is suggested in the treatment of Alzheimer by 
inhibiting Hsp 90 which leads to degradation of Hsp 90 
protein client. Silybin shows an antifibrotic effect by 
reducing the transformation of stellate cells into 
myofibroblasts and down regulates gene expression of 
extracellular matrix components indispensable for fibrosis. 
Silybin treatment resulted to decrease in CDK2 and CDK4 
levels, the apoptosis of ECV304 cells are induced and 
angiogenesis inhibited by modulation of caspases, Bcl-2 
family and NF-kappaB. The growths of some cancers in 
rodents are inhibited by dietary silybin and its potential is 
suggested in treatment of cancer. 
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Figure 2: Pharmacological action of silymarin 
 
APPLICATIONS BY DIFFERENT ROUTE OF 
ADMINISTRATION 
Oral route 
Oral route of drug administration has been known for 
decades and widely accepted method for drug delivery 
because of its simple, convenient, noninvasive, safest, and 
most economical aspect. The challenging problems in oral 
drug delivery includes, difficulty in swallowing pill, irritant 
and unpalatable drugs being not suitable for administration 
by this route, poor stability in the gastric environment, low 
solubility and poor bioavailability, slow onset of action, less 
or no control over drug release, nonspecific delivery site and 
systemic side effects. The Silymarin is BCS class II drug 
having poor bioavailability due to extensive phase II 
metabolism, poor aqueous solubility, low permeability 
across intestinal epithelial cells and rapid excretion in bile 
and urine. To overcome this problems the different types of 
silymarin nanoparticles (NPs), such as liposomes, nano- or 
micro- emulsions, polymeric NPs and solid lipid NPs, 
polymer conjugates, nanocrystals, polymeric micelles, mixed 
micelles inclusion complex, continue to be developed in 
order to improve the stability and bioavailability of 
Silymarin.
 
Table 1: Oral drug delivery of silymarin 
Formulation Composition Preparation method Purpose Ref 
  TABLETS   
Floating Tablet Hydroxypropyl methyl cellulose, 
microcrystalline cellulose, 
crospovidone  
Wet granulation Prolong gastric residence time 15 
Erodible matrix 
tablets 
Glyceryl monostearate, Polyethylene 
glycol 6000, Poloxamer188 
Melt Fusion Controlled release of SLM 16 
Solid dispersion 
tablet 
Hydroxy propyl-  -cylcodextrine 
(HP- -CD)   
Direct compression Enhance dissolution and oral 
bioavailability  
 
17 
Osmotic tablets Cellulose acetate Melt fusion Controlled release of SLM 18 
Fast dissolving Cross povidone, Dry granulation Fast dissolving with improve 
patient compliance and 
19 
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Formulation Composition Preparation method Purpose Ref 
tablet Microcrystalline Cellulose, 
Croscarmellose 
sodium, Aerosil 
convenience 
Microporous 
osmotic pump 
tablet 
Dibutyl phthalate, soyabean lecithin, 
Sodium chloride, lactose, mannitol 
Phytosome complex 
method 
Sustained and controlled-
release drug delivery. 
20 
Nanosuspension 
tablet 
Polyvinyl alcohol, Tween 80, 
mannitol 
Lyophilization Immediate release 21 
  LIPOSOMES   
Liposome Cholesterol Ethanol injection Enhance hepatoprotective and 
gastroprotective effect 
22 
Liposome Lecithin, cholesterol, stearyl amine, 
tween-80 
Reverse evaporation 
technique 
Enhance hepatoprotective 
effect 
23 
Liposome  - amino phenyl- -D- 
Galactopyranoside  
Reverse evaporation 
technique   
Targeting to hepatocyte   24 
Liposome Lecithin, Cholesterol Lipid film hydration 
method 
Targeting to hepatocyte and to 
improve oral bioavailability   
25 
Liposome Soybean phosphatidylcholine, 
sodium glycocholate 
supercritical fluid 
technology 
improve the dissolution and 
bioavailability of silymarin 
26 
Proliposomes Soy-lecithin, 
D-Galactosamine, Superoxide 
dismutase (SOD), 
malondialdehyde (MDA), 
glutathione peroxidase (GSH-PX) 
simple dissolving 
process 
improve bioavailability and 
hepaptoprotective effects 
27 
Proliposomes Phospholipid and mannitol Film deposition Enhanced bioavilability 28 
Proliposomes soybean phospholipids, cholesterol, 
isopropyl myristate and sodium 
cholate 
Film dispersion-freeze 
drying method 
Improve oral bioavailability 29 
Bilosomes Soybean lecithin 
phosphatidylcholine, cholesterol, 
Sodium deoxycholate, 
Sodium taurocholate, Carbon 
tetrachloride 
Film hydration 
technique 
Increase the hepatoprotective 
activity of the drug 
30 
  SOLID- LIPID 
NANOPARTICLE 
  
Solid lipid 
nanoparticle 
               _ High pressure 
homogenization 
Enhanced biodistribution 31 
Solid lipid 
nanoparticle 
ATO 5, lecithin, tween 80  High pressure 
homogenization 
Improve oral bioavailability 32 
Solid lipid 
nanoparticle 
Compritol 888 ATO, soyabean 
lecithin, Poloxamer-188 
Hot and cold 
homogenization 
Enhanced biodistribution and 
bioavailability 
33 
Solid lipid 
nanoparticle 
Campritol 888 ATO Homogenization Enhance oral bioavailability 34 
  SOLID DISPERSION   
Solid Dispersion Polyethylene glycol 6000 Fusion method Enhanced dissolution  rate and 
oral bioavailability 
35,36 
Solid Dispersion Hydroxypropyl methyl cellulose E 
15LV, 
spray drying and co-
precipitation methods 
Enhance silymarin dissolution 37 
Solid Dispersion Polyvinylpyrrolidone Fluid bed technique Enhance dissolution rate 38 
Solid dispersion Polyvinylpyrrolidone Fluid bed techniques Enhance oral bioavailability 39 
Solid Dispersion Polyvinylpyrrolidone K30, supercritical fluids improve the dissolution and 40 
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Formulation Composition Preparation method Purpose Ref 
Hydroxypropyl methyl cellulose K4M 
and hydroxypropyl methyl cellulose 
K15M, Carbon dioxide 
method bioavailability 
Solid Dispersion Hydroxypropyl methylcellulose 
(HPMC) 
Kneading, spray drying, 
coprecipitation 
Enhance dissolution rate 41 
Solid dispersion Tween 80, polyvinylpyrolidone Spray drying method Enhance oral bioavailability 
and dissolution rate 
42 
  EMULSION   
Emulsion Poly(lactic-co-glycolic acid) (PLGA), 
Polycaprolactone (PCL), Sodium 
Alginate, Chitosan, poly(Llactide) 
(PLLA), Eudragit, 
Membrane 
emulsification 
Improve encapsulation 
efficiency and drug loading. 
43  
Nanoemulsion Sefsol-218, tween-80, ethanol Spontaneous 
emulsification 
Enhance bioavailability and 
hepatoprotective activity 
44 
Nanoemulsion Sefsol- 218, polyoxyethylene sorbitan 
monooleate 
Titration method Enhanced oral bioavailability 45,46 
Nanoemulsion Sefsol- 218, 
Kolliphor RH40, polyethylene glycol 
400 
Aqueous titration 
method 
efficient carrier for oral 
delivery of silymarin against 
human hepatocellular 
carcinoma without damaging 
normal 
47 
Nanoemulsion Labrasol ECH, Capryol 90, Transcutol 
HP, Labrafil, oleic acid, Cremophor 
EL, Triacetin 
Aqueous titration 
method 
Improve solubility and oral 
absorption of silymarin 
48 
Nanoemulsion Capryol 90, Solutol HS 15, Transcutol 
HP 
High pressure 
homogenization 
Enhance oral bioavailability 49 
SNEDDS Campul GMO, Tween 20, 
Crehmophore RH40, Transcutol HP 
Phase titration method improve the dissolution, 
permeability, and oral 
bioavailability 
50 
SNEDDS PEG 200, PEG 400, glyceryl 
monooleate, polysorbate 20 and 
polyoxyethy- lene-50-hydrogenated 
castor oil (HCO-50), Transcutol  
Phase titration method Enhance bioavailability and 
dissolution rate 
51 
  MICROPARTICLES   
Microparticles Lecithin, tween-20, tween-80, span-
20, propylene glycol 
Low energy 
emulsification 
techniques 
Enhanced dissolution, 
therapeutic efficiency and 
bioavailability 
52,53 
Microparticles Phospholipid, ethanol, sodium 
cholate, disodium hydrogen 
phosphate, polyvinylpyrrolidone K30 
Freez drying  Improve oral bioavailability 54 
Floating 
microsphere 
Hydroxypropyl methyl cellulose, 
microcrystalline cellulose, 
crosspovidone 
Wet granulation Prolong gastric residence time 55 
  NANO STRUCTURED 
LIPID CARRIER 
  
Nanostructured 
lipid carrier 
Glycerol, monostearate, oleic acid, 
tween 80, caprylic acid, cetyl 
palmitate, stearic acid 
Emulsification and 
ultrasonication method 
Improve solubility, stability 
and oral bioavailability 
56 
Nanostructure 
lipid carrier 
Stearic acid, capryol 90, Brij S20, Emulsion evaporation 
method 
Improve solubility and 
absorption of silymarin 
57 
Binary lipids-
based 
nanostructured 
lipid Carriers 
Oleic acid, Tween-80, Precirol ATO 5, 
egg phosphatidylcholine 
Hot high- pressure 
homogenization 
improve the oral 
bioavailability of silymarin 
58 
 
Nanostructured Capryol 90, Lauroglycol 90, oleic acid, Emulsion evaporation Improve solubility and 
enhance intestinal 
59 
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Formulation Composition Preparation method Purpose Ref 
lipid carrier precirol ATO 5, cetyl palmitate method permeability 
  NANOCRYSTALS   
Nanocrystals Hydroxypropyl-β-CyD high pressure 
crystallization 
enhanced dissolution rate and 
absorbability 
60 
Nanocrystals acetone, acetonitrile, ethanol and 
methanol 
Precipitation method  enhance oral bioavailability, 
and improve solubility 
61 
  NANOPARTICLES   
Eudragit loaded 
nanoparticles 
Eudragit RL100, Polyvinyl alcohol, 
Hydroxypropyl methyl cellulose 
nanoprecipitation 
technique 
Improve the poor 
bioavailability of silymarin 
through buccal delivery. 
62 
porous silica 
nanoparticles 
Octylphenol polyoxyethylene, 
cyclohexane, a-naphthol 
microemulsion and 
ultrasonic corrosion 
methods 
improve oral 
bioavailability 
63  
Nanoparticles Hydroxypropyl methyl cellulose, 
hydroxy propyl-   -cyclodextrin (HP-
  -CD), ethanol 
Freez drying method Improve solubility and 
bioavailability 
64 
 
Nanoparticles Transcutol HP, polysorbate 80 
(Tween 80), castor oil, and 
polyvinylpyrrolidone (PVP K30)  
Spray drying techniques enhanced oral bioavailability 
and provide excellent hepatic 
protection 
65 
Nanoparticles Poloxamer 188, mannitol Emulsion solvent 
evaporation and freez 
drying method 
Improve poor aqueous 
solubility 
66 
  INCLUSION COMPLEX   
Inclusion 
complex 
 - cyclodextrine Kneading method   Enhanced dissolution and 
bioavailability  
67 
Inclusion 
complex 
 - cyclodextrine Kneading, co-
precipitation and 
solvent evaporation 
Enhanced dissolution and 
solubility 
68 
Inclusion 
complex 
Fulvic acid 
  
Physical mixing and 
kneading methods 
improve the solubility and 
dissolution profile 
69 
  NANOMICELLES   
Nanomicelles Soluplus Thin film method Improve the solubility and oral 
absorption  
59 
Nanomicelles Soluplus,    
d-α-tocopherol, polyethylene glycol 
1000 succinate 
Thin film method Improve the solubility and oral 
absorption 
59 
 
 
Topical route: 
The topical route has attracted attention due to its ability to 
deliver drug substance more selectively to a specific site, 
avoidance of gastric irritation, avoiding drug levels 
fluctuations, prevents metabolism of drug, improved 
compliance, and an enhanced suitability for self-medication. 
The topical route of administration provides the delivery of 
drug for both local and systemic effects. The major obstacle 
for topical delivery is stratum corneum and barrier to the 
penetration of many drug substances. The topical 
application of silymarin has received attention because of its 
pharmacological properties such as antioxidant, anti-
inflammatory, and immunomodulatory properties which 
may prevent UV-induced skin disorders like skin cancer, 
erythema, and photoaging. The one of the most challenging 
aspect of drug development is poor aqueous solubility of 
silymarin (3.2 mg/100 ml). To overcome this issues nanogel, 
gels, creams, lotions, microemulsion, dendrimer are 
developed in order to improve solubility, stability and to 
enhance penetration ability of silymarin. 
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Table 2: Topical drug delivery of silymarin 
Formulation Composition Preparation Method Purpose Ref 
  DENDRIMER   
Dendrimer Glycine, proline, lysine, 
Dimethylformamide, 
dichloromethane, trifluoroacetic acid 
Co-precipitation Enhance skin penetration 
and deposition 
70 
Dendrimer Polyamidoamine (PAMAM-G4) , 
polyethylene glycol, folic acid 
Solvent evaporation Deliver the poorly soluble 
drug silybin 
71 
 
       GEL   
Organogel Lecithin, Pluronic F127, isopropyl 
myristate 
       Enhance  skin penetration  72 
  LIPOSOME   
Nanoliposomes Egg lecithin, cholesterol, chloroform, 
methanol 
Extrusion method Enhance penetration 73 
  SOLID LIPID 
NANOPARTICLES 
  
SLN’s Glyceryl monostearate, Tween 80, 
chloroform and methanol 
Micro- emulsion method Improve stability and 
enhance permeation 
74 
SLN’s Glyceryl monostearate, tween 80,  
solutol HS and loturol F68 
Homogenization Sustain release 75 
  MICROEMULSION   
Microemulsion Labrasol, Transcutol Glyceryl 
monooleate, ethyl oleate, oleic acid, 
isopropyl myristate 
Phase titration method Enhance solubility, 
stability and penetration 
76  
  NANOSTRUCTURED LIPID 
CARRIER 
  
Nanostructured 
lipid carriers 
Compritol ATO 888, Pluronic F-68  
 
Hot high- pressure 
homogenization process 
Increase 
permeation 
and reduced toxicity 
77 
 
 
Topical 
nanostructured 
lipid carrier 
Glycerolmomstearate, oleic acid, 
carbopol 980 
Hot high pressure 
homogenization process 
enhanced solubility, 
stability  and  permeation  
78 
 
 
 
CONCLUSION: 
Silymarin is active phytomedicine obtained from silymarium 
plant containing therapeutic efficacy against various 
diseases. The major concern of silymarin is poor 
bioavailability, low aqueous solubility, high metabolism, 
rapid excretion. The other obstacle is route of administration 
(oral and topical route) which hindered potential of 
silymarin. The challenging problems in route of 
administration are low solubility, poor stability in the gastric 
environment, poor bioavalability, less penetration. To 
overcome these issues the review focuses on several novel 
drug delivery strategies such as liposomes, solid lipid 
nanoparticles, nano or micro-emulsions, microspheres, 
nanogels, solid dispersions, nanocrystals, nano structured 
lipid carrier, inclusion complex, dendrimer, micelles have 
been described to enhance bioavailability, increase solubility 
and delivery of silymarin. There are still many challenges 
that need to be resolved such as safety of nanoparticles for 
long-time, interaction with biological systems and patient-
friendly delivery system. 
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